Fig 1: High salt synergized with IL-17 to induced SIK3 mediated expression of tumor metastatic CXCR4 through MMP-9 activation.(A) Schematic of the metastasis mediating CXCL12/CXR4. (B) ELISA-based analysis in the cell supernatant for the CXCL12 expression following co-treatment with high salt and IL-17 along with SIK3 knockdown or MMP-9 inhibitor (10 µM, 2-(N-Benzyl-4-methoxyphenylsulfonamido)-5-((diethylamino)methyl)-N-hydroxy-3-methylbenzamide, ab142180, AbCam, Cambridge, MA) or CXCR4 blocked with specific monoclonal antibody (Santa Cruz, Dallas, TX). (C) Gelatin Zymography to analysis the MMP-9/-2 activity under the above mentioned treatment conditions. (D) Ratio of inducible MMP-9 to constitutive MMP-2 activity under above mentioned treatment conditions. (E) Flow cytometry-based analysis in the membrane localization of the CXCR-4 following co-treatment with high salt and IL-17 along with SIK3 knockdown or MMP-9 inhibitor or CXCL12 blocked with specific monoclonal antibody (Santa Cruz, Dallas, TX). All data represented as mean values ± SEM from four independent experiments. Student-t-test performed for statistical analysis (significance p<0.05).
Supplier Page from Abcam for MMP-9 inhibitor